Novo to invest in TA Associates-backed Biocomposites.

Novo, Novo Nordisk Foundation's wholly owned holding company, agreed to invest in TA Associates-backed Biocomposites, an international medical devices company that engineers, manufactures and markets leading products for use in infection management in bone and soft tissue. Financial terms were not disclosed. As part of the transaction TA, Biocomposites' majority shareholder since 2017, will reinvest in the Company alongside new investor Novo Holdings and Biocomposites' management. The transaction gives TA and Novo Holdings shared control of Biocomposites.